Roivant Sciences ROIV Income Statement
| Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| $638K-55.2% | $691K-76.3% | $921K-81.0% | $1.1M-77.5% | $1.43M-72.7% | ||
| $41.18M-24.6% | $43.27M-30.0% | $45.34M-35.0% | $48.32M-33.0% | $54.62M+49.2% | ||
| $12.57M+542% | $8.34M+396% | -$5.69M-292% | -$11.21M-211% | -$2.84M+74.9% | ||
| —— | $21.59M+201% | $128.5M+166% | -$19.13M-226% | $12.9M— | ||
| —— | -$265.89M-257% | -$113.52M+50.7% | -$223.36M-334% | -$206.48M— | ||
| $320K+56.1% | $700K+170% | $111K-52.6% | $154K-27.7% | $205K+4.6% | ||
| $1.32M— | $430K— | $1.21M-76.1% | $815K+130% | —— | ||
| $0— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $0— | $0— | $0— | $0-100% | $0— | ||
| $16.16M+9,891% | -$3.99M— | $3M— | -$11.75M+53.5% | -$165K-101% | ||
| $63.23M— | —— | —— | -$25M+33.5% | —— | ||
| -$275K-14.1% | -$786K+61.0% | -$846K+48.0% | -$478K+73.7% | -$241K+88.9% | ||
| -$18.45M— | $2.73M-93.4% | $4.39M— | -$128K-101% | —— | ||
| —— | -$8.3M-230% | $3.21M-84.4% | $71K+101% | —— | ||
| $192.56M— | $192.56M— | $192.56M— | $192.56M— | $0— | ||
| —— | $328.19M+220% | —— | -$187.77M+71.6% | -$177.15M— | ||
| —— | —— | —— | -$1.09B-112,409% | —— | ||
| -$163.82M+5.1% | -$196.48M+5.2% | -$185.66M+30.4% | -$204.38M-6.0% | -$172.57M-59.1% | ||
| $1.86M-5.5% | $2.53M+47.7% | $1.94M+23.0% | $1.94M+22.9% | $1.97M+9.7% | ||
| —— | —— | -$5.98M-133% | -$11.08M-98.7% | -$4.23M+90.0% | ||
| —— | —— | —— | $208.29M-67.9% | $295.45M— | ||
| $1.26M+55.5% | —— | $7.85M+688% | $4.04M+318% | $811K+132% | ||
| $51.19M+307% | $118.81M+323% | $68.29M+932% | $30.06M+1,224% | $12.59M+283% | ||
| $77.17M-7.6% | $105M+25.5% | $81.82M+14.2% | $82.18M+63.7% | $83.49M+78.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Roivant Sciences's revenue?
- Roivant Sciences (ROIV) generated $8.3M in revenue over the trailing twelve months, down 71.6% year over year.
- Where does Roivant Sciences's income statement data come from?
- Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
